Study on Dengue Virus Infection Rates and Vaccine Acceptance in Children Aged 9 to 17 in Martinique and Guadeloupe

What this Trial Is About

Dengue fever is a mosquito-borne virus that causes significant health problems in tropical and subtropical regions. There is currently no antiviral treatment, and controlling mosquitoes has limitations. The tetravalent Dengvaxia4 vaccine, authorized in Europe in 2018, is used to prevent dengue in people aged 9 to 45 who have had prior dengue infection and live in areas with high infection rates. This study focuses on estimating dengue virus seroprevalence among 9- to 17-year-olds in Martinique and Guadeloupe, where previous data was limited to adults. Researchers will collect blood samples from children aged 9 to 17 who visit participating hospital departments to measure dengue and Zika virus antibodies. The study also includes a survey for parents or guardians to assess their willingness to accept the dengue vaccine and understand factors influencing vaccine hesitancy. This combined approach aims to support optimal vaccine introduction and better healthcare planning in these regions. Participants will provide a blood sample during hospital visits and complete questionnaires. Researchers will test for dengue and Zika antibodies to determine infection history and vaccine eligibility. They will track dengue seroprevalence, incidence of primary dengue infection, changes in infection risk over time, and vaccine acceptability. The study results will help guide dengue vaccination strategies and improve management of future dengue outbreaks. Participation duration averages about one year for outcome measurements and surveys.

Dengue Vaccine Strategy in Children Aged 9 to 17 Years in the French Caribbean